Recombinant human PAI1 (mutated S) protein (ab92830)

Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • SpeciesHuman
    • Modificationsmutated S

Specifications

Our Abpromise guarantee covers the use of ab92830 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity90 (+/-) 5% active by uPA titration Kinetic Data: Second order rate constants for inhibition of: uPA = 6.3 X 106 M-1s-1 tPA = 5.7 X 106 M-1s-1
  • Applications

    Functional Studies

    SDS-PAGE

  • Purity> 95 % SDS-PAGE.
    > 98% pure by SDS PAGE
  • FormLiquid
  • Additional notesSolubility: > 2 mg/mL and < 5 mg/mL


    This mutant contains a Ser to Cys replacement around the vitronectin binding site. Incorporation of an NBD labels allows for the reporting of binding to vitronectin.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 0.1M Sodium chloride, 0.05M Sodium phosphate, 1mM EDTA, pH 6.6

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • Clade E
    • Endothelial plasminogen activator inhibitor
    • Nexin
    • PAI
    • PAI 1
    • PAI-1
    • PAI1_HUMAN
    • PLANH1
    • Plasminogen activator inhibitor 1
    • Plasminogen activator inhibitor type 1
    • Serine (or cysteine) proteinase inhibitor
    • Serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1
    • Serpin E1
    • Serpin peptidase inhibitor clade E
    • Serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1
    • Serpine 1
    • SERPINE1
    see all
  • FunctionThis inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis.
  • Tissue specificityFound in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells.
  • Involvement in diseaseDefects in SERPINE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]. It is a hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen.
    Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions.
  • Sequence similaritiesBelongs to the serpin family.
  • Post-translational
    modifications
    Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-
    -Met-370 bond.
  • Cellular localizationSecreted.
  • Information by UniProt

Recombinant human PAI1 (mutated S) protein images

  • 10% SDS-PAGE analysis of ab92830
    Lane 1: ab92839 (3µg) Reduced
    Lane 2: ab92839 (3µg) + uPA (10µg) Reduced
    Lane 3: Molecular weight markers

References for Recombinant human PAI1 (mutated S) protein (ab92830)

ab92830 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab92830.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"